2Flood P, Wills P, Lawler P Sir, et al. Review of Australia's plasma fractionation arrangements [ OL]. [2006-01-21 ]. http://www. donateblood. com. au/admin/file/contentl/c5/report-dec06. pdf
3Friedman MA. Testimony on FDA's regulation of blood, blood products, and plasma[OL]. 1997-06-05[2009-01-10]. http:// www. hhs. gov/asl/testify/t970605b. html
4FDA. Compliance program guidance : Chapter 42-blood and blood products inspection of source plasma establishments, brokers, testing laboratories, and contractors-7342. 002 [OL]. 2006-10- 01 [ 2009-01-21 ]. http ://www. aeeessdata. fda. gov/seripts/edvh/efefr/efraeareh. efm
5FDA. Code of federal regulations title 21 ( Food and Drugs), Part 210, 211,600,601,606,607,610,630, and 640. 20084)4- 01[ 2009-01-21 ]. http://www. accessdata. fda. gov/scripts/ cdrh/cfcfr/cfrscarch. cfm
6FDA. Guideline for quality assurance in a blood establishment 1995-137-11 [ 2009-04-10]. http://www. fda. gov/cber/gdlns/ gde_qa. txt
7FDA. Guidance for industry-notifying FDA of fatalities related to blood collection or transfusion [OL]. 2003-09 [ 2009-03-28 ]. http ://www. fda. gov/cber/gdlns/bldfatal. pdf
8FDA. Revised recommendations for red blood cell mmunization programs for source plasma donors[ OL]. 1995-03-03 [ 2009-04- 01 ]. http://www. fda. gov/cber/bldmem/031495. txt
9FDA. Informed consent recommendations for source plasma donors participating in plasmapheresis and immunization programs [OL]. 2007-06 [ 2009-03-20 ]. http://www. fda. gov/cber/ gdlns/donorimmun. htm
3Code of Frederation of Regulation. Current good manufacturing practice for blood and blood components. Washington : US Goveminent Printing Office, 1998-04 BioLife Plasma Services. About Biolife-Press kit [ OL]. http:// www. biolifeplasma. com/html/about _ biolife/BioLife _ PressKit.
4WHO. Twenty-eighth world health assembly. WHA28.72 Utilization and supply of human blood and blood products. Geneva : WHO, 1975-03-13-30 [ 2009-10-13 ] http: //www. who int/ bloodsafetg/en/WHA28.72.pdf.
5WHO. Twenty-eighth world health assembly. WHA28.72 Utilization and supply of human blood and blood products. Geneva : WHO, 1975-03-13-30 [ 2009-10-13 ] http: //www. who int/ bloodsafetg/en/WHA28.72, pdf.
6WHO. Requirements for the collection, processing and quality control of blood components and plasma derivatives (revised 1992)//WHO,technical report series No 840[ S/OL]. Geneva: WHO, 1994 [ 2009-10-14 ] http ://www. who. int/bloodproducts/ publications/WHO.TRS_840-A2. pdf.
7WHO. WHO expert committee on biological standardization. 52 nd Report [ S/OL]. [ 2009-10-13 ] http://whqlibdoc.who. int/ trs/WHO. TRS_924. pdf.
9Council of Europe, Guide to the preparation, use and quality assurance of blood components( 1995 ). Brussels :Council of Europe Publishing, 1995 : 113-139.
10Therapeutic Goods Administration. The Australian code of good manufacturing practice (GMP) for blood and blood products[ S/ OL]. 2000-08-24[ 2009-10-13 ] http ://www. tga. gov. au/manuf/ gmpbltic.pdf.
